JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kodama, K.
Right arrow Articles by Adachi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kodama, K.
Right arrow Articles by Adachi, H.

Vol. 290, Issue 2, 748-752, August 1999

Improvement of Mortality by Long-Term E4010 Treatment in Monocrotaline-Induced Pulmonary Hypertensive Rats

Kohtarou Kodama and Hideyuki Adachi

Cardiovascular Research Unit, Tsukuba Research Laboratories, Eisai Co., Ltd., Tsukuba, Ibaraki, Japan

We investigated the effects of long-term treatment with a selective phosphodiesterase 5 inhibitor E4010, 4-(3-chloro-4methoxybenzyl)amino-1-(4-hydroxypiperidino)-6-phthalazinecarbonitrile monohydrochloride, on the survival rate of rats with pulmonary hypertension induced by monocrotaline (MCT). After an s.c. injection of 40 mg/kg MCT (day 0), male Wistar rats of 4 weeks of age were divided into four groups. Vehicle-treated rats (control, n = 8) and MCT-treated rats (n = 32) were fed a commercial diet. E4010-treated rats were given a commercial diet containing 0.01% (E4010 0.01%, n = 32) and 0.1% (E4010 0.1%, n = 32) of E4010, respectively. At day 23, all rats in the control group and 28.1% of those in the MCT group (P < .01 versus control) were alive. Although the survival rate of E4010 0.01%-treated rats was not improved (50%) compared with MCT, those at 0.1% showed a significant difference (84.4%, P < .01 versus MCT). For MCT rats (n = 9), right ventricle weight and the levels of plasma atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), cGMP, and cyclic AMP were higher compared with control (n = 8). In E4010 0.1%-treated rats (n = 27), the right ventricular hypertrophy was suppressed, and the increase in plasma cGMP level was amplified compared with MCT without any effects on plasma ANP, BNP, and cyclic AMP levels. Accordingly, we consider that the mechanism of action of E4010 may be related to the decreased pulmonary arterial pressure caused by the augmentation of pulmonary arterial relaxation through an ANP and/or BNP-cGMP system. These results suggest that E4010 will be useful for the treatment of pulmonary hypertension.

0022-3565/99/2902-0748$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Eur Respir JHome page
E. Dony, Y-J. Lai, R. Dumitrascu, S. S. Pullamsetti, R. Savai, H. A. Ghofrani, N. Weissmann, C. Schudt, D. Flockerzi, W. Seeger, et al.
Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition
Eur. Respir. J., March 1, 2008; 31(3): 599 - 610.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
M. Clozel, P. Hess, M. Rey, M. Iglarz, C. Binkert, and C. Qiu
Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
Experimental Biology and Medicine, June 1, 2006; 231(6): 967 - 973.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. Ladha, S. Bonnet, F. Eaton, K. Hashimoto, G. Korbutt, and B. Thebaud
Sildenafil Improves Alveolar Growth and Pulmonary Hypertension in Hyperoxia-induced Lung Injury
Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 750 - 756.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. B. Yap, D. Mukerjee, P. M. Timms, H. Ashrafian, and J. G. Coghlan
Natriuretic Peptides, Respiratory Disease, and the Right Heart
Chest, October 1, 2004; 126(4): 1330 - 1336.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, A. Samidurai, S. Pullamsetti, N. Weissmann, C. Schudt, L. Ermert, W. Seeger, and F. Grimminger
Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary Hypertension
Circ. Res., April 30, 2004; 94(8): 1101 - 1108.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, H. Yilmaz, G. Butrous, L. Ermert, M. Ermert, N. Weissmann, F. Rose, A. Guenther, et al.
Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats
Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 39 - 45.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. Itoh, N. Nagaya, T. Fujii, T. Iwase, N. Nakanishi, K. Hamada, K. Kangawa, and H. Kimura
A Combination of Oral Sildenafil and Beraprost Ameliorates Pulmonary Hypertension in Rats
Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 34 - 38.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. Chen, X. T. Gan, J. V. Haist, Q. Feng, X. Lu, S. Chakrabarti, and M. Karmazyn
Attenuation of Compensatory Right Ventricular Hypertrophy and Heart Failure following Monocrotaline-Induced Pulmonary Vascular Injury by the Na+-H+ Exchange Inhibitor Cariporide
J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 469 - 476.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.